Cargando…

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial

Multiple myeloma (MM) is a plasma cell malignancy expressing B cell maturation antigen (BCMA). Elranatamab, a bispecific antibody, engages BCMA on MM and CD3 on T cells. The MagnetisMM-1 trial evaluated its safety, pharmacokinetics and efficacy. Primary endpoints, including the incidence of dose-lim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bahlis, Nizar J., Costello, Caitlin L., Raje, Noopur S., Levy, Moshe Y., Dholaria, Bhagirathbhai, Solh, Melhem, Tomasson, Michael H., Damore, Michael A., Jiang, Sibo, Basu, Cynthia, Skoura, Athanasia, Chan, Edward M., Trudel, Suzanne, Jakubowiak, Andrzej, Gasparetto, Cristina, Chu, Michael P., Dalovisio, Andrew, Sebag, Michael, Lesokhin, Alexander M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579053/ https://www.ncbi.nlm.nih.gov/pubmed/37783970 http://dx.doi.org/10.1038/s41591-023-02589-w

Ejemplares similares

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
por: Lesokhin, Alexander M., et al.
Publicado: (2023)

P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
por: Dalovisio, A., et al.
Publicado: (2022)

P880: EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A SUBGROUP ANALYSIS FROM MAGNETISMM-3
por: Leleu, Xavier, et al.
Publicado: (2023)

S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM-3
por: Mohty, Mohamad, et al.
Publicado: (2023)

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3
por: Lesokhin, A. M., et al.
Publicado: (2022)

P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES
por: Manier, Salomon, et al.
Publicado: (2023)

P906: GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A
por: Rodríguez-Otero, Paula, et al.
Publicado: (2023)

P907: EFFICACY AND SAFETY OF ELRANATAMAB IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3
por: Touzeau, Cyrille, et al.
Publicado: (2023)

P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2
por: Leleu, Xavier, et al.
Publicado: (2023)

PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Fonseca, R., et al.
Publicado: (2022)

PB2131: MAGNETISMM-7: AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF ELRANATAMAB VERSUS LENALIDOMIDE IN POST-TRANSPLANT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Manteca, Maria Victoria Mateos, et al.
Publicado: (2023)

PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Grosicki, Sebastian, et al.
Publicado: (2023)

P957: AN INDIRECT COMPARISON OF ELRANATAMAB’S (ELRA) OBJECTIVE RESPONSE RATE (ORR) FROM MAGNETISMM-3 (MM-3) VERSUS REAL-WORLD EXTERNAL CONTROL ARMS IN TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM)
por: Costa, Luciano, et al.
Publicado: (2023)

P908: IDENTIFICATION OF CYTOKINES ASSOCIATED WITH RESPONSE AND CYTOKINE RELEASE SYNDROME – ANALYSIS OF MAGNETISMM-3 COHORT A
por: Weisel, Katja, et al.
Publicado: (2023)

Elrexfio™ (elranatamab-bcmm): The game-changer in treatment of multiple myeloma
por: Rais, Taruba, et al.
Publicado: (2023)

Addition to Contract No. 35/PS with Fabrica Italiana Magneti Marelli, Milano, for the Radio Frequency System
Publicado: (1959)

Selective Adsorption Behavior and Mechanism for Cd(II) in Aqueous Solution with a Recoverable Magnetie-Surface Ion-Imprinted Polymer
por: Ye, Siqing, et al.
Publicado: (2023)

Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case
por: Mutlu, Yasa Gul, et al.
Publicado: (2023)

Emerging therapeutic agents for lung cancer
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2016)

A caccia del bosone di Higgs: magneti, governi, scienziati e particelle nell'impresa scientifica del secolo
por: Maiani, Luciano, et al.
Publicado: (2013)

Glanzmann’s thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options
por: Solh, Tia, et al.
Publicado: (2015)

Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice
por: Sengsayadeth, Salyka, et al.
Publicado: (2021)

Autoimmune Demyelinating Polyneuropathy as a Manifestation of Chronic Graft-versus-Host Disease after Adult Cord Blood Transplantation in a Patient with Chronic Lymphocytic Leukemia
por: Hogan, Fredrick, et al.
Publicado: (2014)

Securing the graft during pandemic: are we ready for cryopreservation for all?
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2020)

Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia
por: Marvin-Peek, Jennifer, et al.
Publicado: (2022)

Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments
por: Geethakumari, Praveen Ramakrishnan, et al.
Publicado: (2021)

Chimeric antigen receptor‐T cell therapies: The changing landscape
por: Sengsayadeth, Salyka M., et al.
Publicado: (2021)

CAR T cell therapy in solid tumors: A review of current clinical trials
por: Patel, Urvi, et al.
Publicado: (2021)

Cancer immunotherapy beyond immune checkpoint inhibitors
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018)

Role of bridging therapy during chimeric antigen receptor T cell therapy
por: Bhaskar, Shakthi T., et al.
Publicado: (2021)

Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
por: Yee, Andrew J, et al.
Publicado: (2012)

Panobinostat and Multiple Myeloma in 2018
por: Yee, Andrew J., et al.
Publicado: (2018)

How We Approach Smoldering Multiple Myeloma
por: Raje, Noopur, et al.
Publicado: (2020)

Chimeric antigen receptor T‐cell therapy: Challenges and framework of outpatient administration
por: Gatwood, Katie S., et al.
Publicado: (2021)

Chimeric Antigen Receptor T-Cells: The Future Is Now
por: Mchayleh, Wassim, et al.
Publicado: (2019)

Un metodo generale per il calcolo delle matrici di transferimento di un canale magnetico per particelle cariche costituito da quadrupoli e magneti analizzatori
por: Uccelli, Fabio, et al.
Publicado: (1962)

Next generation of immune checkpoint therapy in cancer: new developments and challenges
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018)

Antimicrobial de-escalation in patients with high-risk febrile neutropenia: Attitudes and practices of adult hospital care providers
por: Gorsline, Chelsea A., et al.
Publicado: (2021)

Reply to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology
por: Raje, Noopur, et al.
Publicado: (2019)

Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
por: Bernstein, Zachary S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gumjarbg93fksj9pl6oii4uspp